



## **Imprimis Pharmaceuticals to Host its First Quarter 2015 Financial Report Conference Call and Webcast on May 13, 2015 at 4:30 p.m. EDT**

May 4, 2015

SAN DIEGO, May 4, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today reported that it will release its first quarter 2015 financial results on Wednesday, May 13, 2015. The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.



To participate in this event, dial 877-407-8035 domestically or 201-689-8035 internationally, approximately 5 to 10 minutes prior to the start of the call. Additionally, you can listen to the event online at <http://www.investorcalendar.com/event/173998>, as well as at the company's website at [www.imprimispharma.com](http://www.imprimispharma.com). If you are unable to participate during the live webcast, the event archive will be available at <http://www.investorcalendar.com/event/173998> or at the company's website at [www.imprimispharma.com](http://www.imprimispharma.com). You may access the teleconference replay by dialing 877-660-6853 domestically or 201-612-7415 internationally, referencing conference 13609032. The replay will be available until June 13, 2015.

### **IMPRIMIS PHARMACEUTICALS**

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis' business is focused on its proprietary ophthalmology and urology drug formulations. The company's pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis. For more information about Imprimis, please visit the company's corporate website at [www.ImprimisPharma.com](http://www.ImprimisPharma.com); ophthalmology business websites at [www.GoDropleless.com](http://www.GoDropleless.com) and [www.LessDrops.com](http://www.LessDrops.com); and urology business website at [www.DefeatIC.com](http://www.DefeatIC.com).

### **SAFE HARBOR**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to

obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at [www.sec.gov](http://www.sec.gov). Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

**Investor Contact**

Bonnie Ortega  
[bortega@imprimispharma.com](mailto:bortega@imprimispharma.com)  
858.704.4587

Logo - <http://photos.prnewswire.com/prnh/20150108/167712LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-to-host-its-first-quarter-2015-financial-report-conference-call-and-webcast-on-may-13-2015-at-430-pm-edt-300076254.html>

SOURCE Imprimis Pharmaceuticals, Inc.